EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
Marc Dooms approached me regarding the use of the European Reference Network (ERN) for the exchange on off-label use. He would like EAHP to establish a contact list of interested hospital pharmacists that are working with the ERN on different initiatives. The contact list could be used by Marc and interested EAHP members to exchange on topics related to off-label use. ERN initiatives that should be targeted first are ERN EpiCare (epilepsies), ERN Skin (Skin dosorders), MetaERN (metabolic disorders) and ERN PaedCan (pediatric cancer). EAHPs role in this would be contacting the different initiatives and asking them for providing us with contact details of hospital pharmacist that are active within the initiative. Do you think we could help Marc?
Andras pointed out that a lot of people are only reading the summary of our positions on the first page of the position paper. I already updated the website and included a mention that these positions should be read in conjunction with the supporting information in the paper. In addition, I will include a more elaborate article in the next EU Monitor.
Catarina finished the front and the back cover of the publication. For the print version, I would suggest using the new address on the back cover. Please find here the different covers: front – July; front – August; back – old address; back – new address
Do you like the covers?
Follow-up from the CTF Stakeholder Meeting TBC if there is anything that needs to be done over the summer in accordance with the points discussed during the CTF Stakeholder Meeting.
EAHP, HOPE and Andreas Walter from EMVO will be meeting with Unit B4 of the European Commission to discuss hospital integration. The meeting will take place on 12 July at 11.00 am. I will provide you with a short report during the policy call.
Did you have time to check the draft document containing information on the selection of members for the “Statute and SOP Review Committee” that I sent to you at the beginning of July?
We still need somebody that could respond to the EMA clinical data publication survey. The person that provides comments must have used the clinical data available on EMAs website. The submission deadline is 31st August.
Regarding the other 2 consultations which are due by the end of August (Commission – tissue and blood legislation/ EMA – chronic non-infectious liver diseases) I have not yet heard back from Kees or the SC. I will follow up with Kees.
For those EMA consultations due at the end of July, I will ask Petr to check the final comments, since you will be on holidays. For the FIP consultation on mHealth I am waiting on input from Rob regarding mHealth applications used by pharmacists.
RPP-Group – call for action on skin disinfectants
I spoke to RPP about the call for action. The initiative is supported and funded by BD. The first step of the initiatives aims at closing the regulatory gap by issuing guidelines/ recommendations on the distinction between biocidal products and medicinal products regarding the classification of disinfectants to be used for skin antisepsis before surgery and injection. The call for action will be issued by a letter from an MEP to the Commission. Alternatively or additionally RPP is also open to approaching other institutions such as EMA. RPP is also open for comments on the call or other suggestions. They aim at issuing the call in September. Follow up actions, i.e. initiatives relating to the correct use of skin disinfectants are not yet planned. They are however open to ideas once the call for action takes off.
German event on access to medicines
On Monday I went to an event hosted by the representation of the German region Bavaria on the access to medicines – Challenges and perspectives for Europe. The Bavarian Minister for Health and Care and the Director General of DG SANTE gave each a keynote speech before a panel – consisting out of representatives from the German pharma industry, one MEP (Dr Peter Liese) and one patient representative (European Patients’ Forum and Director European Federation of Allergy and Airways Diseases Patients’ Associations) – started a discussion on the topic. The group covered a large number of topics, i.e. shortages, procurement, pricing and reimbursement, innovation, moving the production to Europe, raising production standards of medicines/ active substances in China/India, streamlining of data requirements for marketing authorisations and reimbursement, FMD and HTA. The MEP pointed out that the ENVI committee spoke to Juncker recently to bring his attention to the fact that his Commission has not produced one legislative proposal on health. Especially shortages are of importance for the MEP. He mentioned in his interventions that an industrial strategy for the supply of medicines could be a first step towards raising awareness on the issue.
